Tirzepatide 10 mg

Tirzepatide 10 mg is Hilma Biocare's dual GIP and GLP-1 receptor agonist, supplied as a single lyophilised vial. It produces stronger metabolic effects than GLP-1 agonism alone and is one of the most researched weight-management molecules.

What Tirzepatide Is

Tirzepatide is a synthetic peptide that activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. That dual action is what separates it from pure GLP-1 agonists such as semaglutide. By engaging two incretin pathways, it produces greater effects on appetite, gastric emptying and insulin sensitivity. The 10 mg vial is the standard research presentation.

The History of Tirzepatide

Tirzepatide was developed by Eli Lilly and approved in 2022 as Mounjaro for type 2 diabetes, following the SURPASS trials. The SURMOUNT-1 trial then showed substantial weight loss in adults with obesity, and it was approved for weight management as Zepbound in 2023. It was the first dual incretin agonist to reach the market and set a new benchmark for metabolic therapy.

How It Works

Tirzepatide binds GIP and GLP-1 receptors in the pancreas, hypothalamus and gut. GLP-1 activation reduces appetite and slows gastric emptying, while GIP activation adds to insulin secretion and may improve fat metabolism. The molecule is engineered for a long half-life through albumin binding and resistance to DPP-4. It is cleared through proteolytic degradation.

What the Research Shows

• SURPASS trials established glycaemic control in type 2 diabetes.
• SURMOUNT-1 showed substantial weight loss in adults with obesity.
• Dual agonism produces greater effects than GLP-1 alone in trials.
• Gastrointestinal effects are the most common adverse events.

Research Context

Tirzepatide's clinical programme produced some of the largest weight-loss results seen in a phase 3 trial. SURMOUNT-1 reported reductions of around 20 to 22 percent at the highest dose over 72 weeks, and SURPASS showed superior glycaemic control compared with semaglutide in type 2 diabetes. The dual GIP and GLP-1 mechanism is thought to explain part of that advantage. As with other incretins, gastrointestinal effects are the main tolerability concern, and long-term outcome data continues to accumulate. The dual mechanism is also being studied for effects on liver fat and on cardiovascular risk markers, where early data has been encouraging.

Strength, Pack and Authentication

Each vial contains 10 mg of lyophilised tirzepatide, sealed and packed in a printed carton stating the compound, strength and vial count. A scratch-off security code inside the box can be verified against Hilma Biocare's records. The powder is stable before reconstitution and intended for research use only.

Buying Tirzepatide Online

Tirzepatide is one of the most searched metabolic peptides. If you are researching tirzepatide 10 mg, comparing dual agonists or looking to buy tirzepatide online from a trusted Hilma Biocare supplier, this page gives you the full specification, pack size, price and live stock status. Browse more Hilma Biocare metabolic peptides at NotNatty.